Recent data from a study in Brazil has shown that a needleless injection system can make Fuzeon (enfuvirtide) administration easier and more comfortable. The gas powered injection system called the Biojector 2000 produced drug availability similar to conventional subcutaneous injections that use a needle and syringe. In addition, the study illustrated many benefits of a needleless system over the conventional injection method. They include:
- fewer injection site reactions
- eases the fears of "needlephobic" patients
- increased comfort
- ease of administration
- less risk of needlestick injuries
- ease of disposal
- improved adherence and acceptance of Fuzeon
While the Biojector 2000 is not readily available at this time, its manufacturer, Bioject, has filed for FDA approval for its use with Fuzeon. It is not yet known whether the FDA will issue an approval.
Important Update!
As of October 2007, the makers of Fuzeon, Roche and Trimeris, have decided not to pursue their plan to market their drug Fuzeon with the Biojector 2000. They site severe side effects from the Biojector 2000 as the cause. Read more about their decision.
Sources:
